| Document |
Document Title |
|
WO/2023/137947A1 |
The present invention relates to the technical field of vaccine preparation, and in particular to an immune-enhancing delivery system formed by targeted antigen delivery by CCL11. The system further enhances immunogenicity by fusing a ch...
|
|
WO/2022/111713A9 |
Provided are a polypeptide containing disulfide bonds and capable of inhibiting activity of serine protease, and a use thereof, relating to three types of linear polypeptide molecules, respectively capable of inhibiting the activity of s...
|
|
WO/2023/137945A1 |
The present invention relates to the field of molecular biology, and in particular relates to the use of CXCL14. According to the present invention, different antigen proteins are transferred to the surface of a DC cell by means of the c...
|
|
WO/2023/138333A1 |
Provided is a recombinant SARS-CoV-2 protein, containing at least two artificially constructed non-natural RBD fragments. A recombinant vaccine using the recombinant SARS-CoV-2 protein as a target antigen has a broad-spectrum protection ...
|
|
WO/2023/138679A1 |
Provided is a method for synthesizing a flavonoid compound. The method comprises providing a recombinant prokaryotic cell, wherein, in the prokaryotic cell, the transmembrane protein rhodanese Ygap of Escherichia coli is up-regulated or ...
|
|
WO/2023/137946A1 |
The chemotactic binding ability of CCL13 and an immune cell surface receptor such as DC cells is used to transport different antigenic proteins to the surface of the DC cells, the efficiency of phagocytosis, processing, and presentation ...
|
|
WO/2023/138573A1 |
A disulfide bond-modified polypeptide complex comprising interleukin 21 and a receptor thereof. For IL-21 and IL-21Rα, an unnatural interchain bond is formed between a first mutant residue of IL-21 and a second mutant residue of IL-21RÎ...
|
|
WO/2023/137741A1 |
Provided are an immunocyte, and a preparation method therefor and the use thereof. A promoter is inserted into the upstream of a gene for αE subunit of a CD103 protein in the immunocyte, resulting in the enhanced and stable expression o...
|
|
WO/2023/136342A1 |
The present invention provides a cyclic peptide represented by formula (I) or a pharmaceutically acceptable salt thereof. [In the formula, A is selected from ring-forming groups A1-A5; Xaa1 is a residue of an aromatic amino acid; Xaa2 is...
|
|
WO/2023/135210A1 |
The invention relates to vesicles comprising : 1) a first fusion protein, the first fusion protein comprising: la) a polypeptide capable of binding to a protein on the membrane of a eukaryotic cell, and 2a) a polypeptide capable of bindi...
|
|
WO/2023/134742A1 |
A three-target anti-tumor drug, and a preparation method therefor and the use thereof. A fusion protein can be efficiently expressed, has a long half-life in vivo, a high stability and a good tumor inhibitory effect.
|
|
WO/2023/133617A1 |
The present technology discloses the production process for a chimeric protein with SEQ ID no. 1, using the nucleotide sequence with SEQ ID no. 2. It also discloses the chimeric protein defined by SEQ ID no. 1, the gene in SEQ ID no. 2 u...
|
|
WO/2023/137143A1 |
The present invention relates, inter alia, to methods for making a variety of proteins, especially proteins having an Fc domain and/or a Fab domain. For instance, the present invention provides methods which overcome common purification ...
|
|
WO/2023/131053A1 |
Provided are construction of a T cell receptor and the use thereof. The mutation of α-chain and β-chain intracellular constant region sites of the T cell receptor inhibits the degradation of the T cell receptor after the activation of ...
|
|
WO/2023/131276A1 |
An isolated antigen binding protein, capable of targeting MSLN. The isolated antigen binding protein comprises at least one CDR in an antibody heavy chain variable region VH, and the VH comprises an amino acid sequence shown in any one o...
|
|
WO/2023/130667A1 |
Provided is a catenated VAR2CSA recombinant protein, a preparation therefor and a use thereof. The catenated VAR2CSA recombinant protein comprises a binding domain, SpyTag, a p53dim structural domain, and SpyCatcher, which are randomly a...
|
|
WO/2023/131193A1 |
Provided is a humanized monoclonal antibody against a human B7-H3 molecule. The monoclonal antibody against human B7-H3 is hu4G4, and comprises a heavy chain and a light chain; the amino acid sequence of a heavy chain variable region (VH...
|
|
WO/2023/133488A1 |
Described herein are methods of ablating a cell population using chimeric antigen receptors (CARs) targeting CD37, as well as related molecules and methods.
|
|
WO/2023/130462A1 |
The present invention relates to a chimeric antigen receptor targeting IL13Rα2, a nucleic acid molecule encoding same, a vector containing the nucleic acid molecule, and an immune effector cell (e.g., a T cell and an NK cell) engineered...
|
|
WO/2023/130187A1 |
Disclosed is a peptide including (a) a cell membrane penetration (CMP) sequence; and (b) one or more TDP-43 phosphorylation-blocking (PB) sequences. Also disclosed is a method of reducing the phosphorylation of TDP-43 in a cell, the meth...
|
|
WO/2023/125796A1 |
Provide are full human anti-FAPα antibodies and variants thereof with further optimized CDR sequences. The new antibodies exhibited high affinity to the FAPα protein and can be used to treat cancers and inflammatory conditions.
|
|
WO/2023/125520A1 |
The present invention relates to a camel-derived nanobody specifically binding to a SARS-CoV-2 S protein and an antigen-binding fragment thereof, and specifically relates to a camel-derived nanobody or an antigen-binding fragment thereof...
|
|
WO/2023/125881A1 |
The present invention relates to a fusion protein of GLP-1 and GDF15 and the use thereof. The fusion protein comprises a first polypeptide fragment, a second polypeptide fragment and a third polypeptide fragment which are sequentially co...
|
|
WO/2023/125178A1 |
The present invention belongs to the technical fields of genetic engineering and polypeptide preparation; disclosed are a fusion protein and a method for preparing a semaglutide intermediate polypeptide therefrom. The fusion protein comp...
|
|
WO/2023/126949A1 |
A composition comprising a peptide nucleic acid (PNA) molecule comprising a nucleotide base sequence configured to bind to a target polynucleotide molecule; and a degron protein covalently bound to the PNA, wherein binding of the PNA to ...
|
|
WO/2023/123776A1 |
Provided are a growth hormone fusion protein and a preparation method and use thereof. The growth hormone fusion protein includes: a double-stranded structure having a first constant region Fc segment and a second constant region Fc segm...
|
|
WO/2023/124741A1 |
A recombinant hybrid protein, a nucleic acid molecule encoding the recombinant hybrid protein, a transgenic expression cassette containing the nucleic acid molecule, and a gene delivery system containing the transgenic expression cassett...
|
|
WO/2023/126009A1 |
The present invention provides a polymer molecule, a monomeric structure and a polymeric structure comprising same, a related product, a preparation method, and uses. A polymer blocking the binding to a receptor is formed by means of the...
|
|
WO/2023/125766A1 |
The present invention provides a chimeric antigen receptor targeting CS1, comprising an extracellular antigen recognition domain, a hinge region, a transmembrane region and an intracellular domain, wherein the extracellular antigen recog...
|
|
WO/2023/122882A1 |
Provided by the present invention are a bispecific T-cell engager, recombinant oncolytic virus thereof, and use thereof. The present invention provides αCD47 and αCD3 bispecific T-cell engagers. The present invention also provides an i...
|
|
WO/2023/125975A1 |
Provided are a nanobody against FLT3, a vector, and an engineered immune cell constructed therefrom and targeting FLT3 highly expressing tumor cells, which can specifically bind to human FLT3, and have high affinity and a significant in ...
|
|
WO/2023/118670A1 |
The present disclosure is directed to a method for screening a signal peptide for efficient expression and secretion of a heterologous polypeptide in mammalian cells, the method comprising the steps of: providing a pool of viral expressi...
|
|
WO/2023/120643A1 |
The present disclosure relates to a CXCR3 ligand having CXCR3-expressing cell migration activity, and specifically relates to amino acid modification and an amino acid sequence that are important for CXCR3-expressing cell migration activ...
|
|
WO/2023/115896A1 |
The present disclosure relates to the field of biomedicine, and specifically relates to a bispecific NK cell agonist, a preparation method, and an application. The present disclosure provides a fused protein. The fused protein uses a CD1...
|
|
WO/2023/116771A1 |
The present invention provides an antibody combined with human MASP-2, a preparation method therefor, and an application thereof. The monoclonal antibody of the present invention specifically binds to a MASP-2 antigen, and has high affin...
|
|
WO/2023/115194A1 |
A nucleic acid construct comprising a polynucleotide that encodes for a secretory protein, the secretory protein comprising a non-secretory protein having a signal sequence domain and a cell penetrating peptide (CPP) sequence domain. Als...
|
|
WO/2023/119295A1 |
LILRB polypeptides are provided. Accordingly, there is provided a LILRB polypeptide capable of binding an HLA-G polypeptide as set forth in SEQ ID NO: 3 and having at least one mutation located within amino acid positions 40-60 of a DI d...
|
|
WO/2023/116751A1 |
The present invention relates to the biopharmaceutical field. The present invention discloses an anti-human ANGPTL3 nanobody. The present invention further discloses a method for preparing a fusion protein (anti-hANGPTL3 VHH-Fc) formed b...
|
|
WO/2023/120658A1 |
An enzyme according to the present invention has activity to convert uridine in RNA to cytidine. A complex according to the present invention comprises said enzyme and a sequence recognition module that causes uridine generated in mRNA b...
|
|
WO/2023/109847A1 |
A PD-L1 antigen binding protein and an application thereof. The antigen binding protein has one or more of the following properties: binding to a PD-L1 protein at an EC50 value of 0.07 μg/ml or above; blocking binding between the PD-L1 ...
|
|
WO/2023/109257A1 |
The present application provides a humanized BCMA single-chain variable fragment (scFv), and also provides a chimeric antigen receptor constructed by using the humanized BCMA single-chain variable fragment. The chimeric antigen receptor ...
|
|
WO/2023/114829A1 |
The invention provides stabilized IL-18 polypeptides and methods of making and using the same.
|
|
WO/2023/111983A1 |
Provided herein are methods, nucleic acids, transformed yeast cells, and kits useful for rapid and effective multiplexed identification of nanobody binding to a target protein domain.
|
|
WO/2023/108929A1 |
Provided are a targeted DNA demethylation method (Mini-CRISD) and a fusion protein used therein. According to the Mini-CRISD method, an engineered reduction ROS1 demethylation effector is delivered to a specific DNA sequence and/or a spe...
|
|
WO/2023/108299A1 |
The present invention relates to polypeptides capable of limiting the replication of coronavirus and/ or nucleic acid molecules encoding polypeptides capable of limiting the replication of coronavirus, including those comprising a Nsp1-1...
|
|
WO/2023/108803A1 |
Provided are a fusion protein, and a preparation method therefor and the use thereof. The fusion protein comprises a GSDME mutant protein and a tumor cell-specific cell-penetrating peptide. In the GSDME mutant protein, a tumor-targeting ...
|
|
WO/2023/110983A1 |
The present invention relates to a method of producing a designed repeat domain which has binding specificity for two targets, wherein binding of such repeat domain to its two targets is mutually exclusive. Said designed repeat domain is...
|
|
WO/2023/109962A1 |
The present invention provides an antibody binding to human CD73, a preparation method therefor, and a use thereof. The monoclonal antibody of the present invention can bind to a CD73 antigen with high specificity, has high affinity, has...
|
|
WO/2023/112028A1 |
Compositions comprising a fragment of a first human receptor target of myasthenia gravis autoantibodies or an analog or derivative thereof and a fragment of a second human protein receptor of myasthenia gravis autoantibodies or an analog...
|
|
WO/2023/109514A1 |
The present invention relates to a membrane integrated fusion protein, a cell comprising same, and use thereof. Specifically provided is a membrane integrated fusion protein, comprising an integration domain and a functional polypeptide ...
|
